本页面由Tiger Trade Technology Pte. Ltd.提供服务

Redhill Biopharma Ltd

0.9200
-0.0255-2.70%
盘后0.92000.00000.00%16:04 EST
成交量:1.45万
成交额:1.34万
市值:468.49万
市盈率:-0.15
高:0.9546
开:0.9395
低:0.9100
收:0.9455
52周最高:3.47
52周最低:0.8802
股本:509.23万
流通股本:332.99万
量比:0.43
换手率:0.44%
股息:- -
股息率:- -
每股收益(TTM):-6.0249
每股收益(LYR):-6.7096
净资产收益率:-1708.61%
总资产收益率:-25.32%
市净率:-1.06
市盈率(LYR):-0.14

数据加载中...

2026/01/22

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2026/01/22

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/12/31

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/06/30

SEC问询函

Form CORRESP - Correspondence
2025/06/25

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/04/10

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/26

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/14

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/16

SEC问询函

Form CORRESP - Correspondence
2024/06/20

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/08

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/15

SEC问询函

Form CORRESP - Correspondence
2024/02/09

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/02/02

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/01

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/08

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/10/26

SEC问询函

Form CORRESP - Correspondence
2023/08/10

SEC问询函

Form CORRESP - Correspondence
2023/06/29

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/04/28

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]